Skip to main content

Table 1 Comparison of demographic and peak biochemical data within a week of admission in survivors and non-survivors [mean ± SD or median (Q25 − Q75)].

From: Serum mAST/ALT ratio had high predictive value for adverse outcome of severe fever with thrombocytopenia syndrome with severe condition

parameters

survivors

non-survivors

P-value

N (%)

289 (81.4)

66 (18.6)

-

Age (year)

65.2 ± 11.1

71.7 ± 8.7

< 0.001

Gender (M/F)

113/176 (39.1/60.1)

36/30(54.5/45.5)

0.02

Hospital stay (days)

11.6 ± 7.1

5.7 ± 4.4

< 0.001

ALT (U/L)

71.7 (44.4, 135)

122.9 (57.3, 224.8)

< 0.001

AST (U/L)

136 (74.2, 266.2)

371.3 (209.0, 750.7)

< 0.001

AST/ALT ratio

1.94 (1.4, 2.56)

3.52 (2.52, 4.54)

< 0.001

GGT (U/L)

31 (18, 58)

52 (23, 139.3)

< 0.001

ALP (U/L)

64 (51, 80)

78 (58.2, 158.5)

< 0.001

mAST (U/L)

34.3 (19.4, 68.7)

92.7 (55.2, 155.7)

< 0.001

mAST/AST ratio

0.242 (0.210, 0.258)

0.254 (0.245, 0.26)

< 0.001

mAST/ALT ratio

0.49 (0.35, 0.63)

0.77 (0.59, 1.02)

< 0.001

cAST (U/L)

101.4 (55.9, 194.8)

278.6 (153.8, 594.4)

< 0.001

cAST/ALT ratio

1.45 (1.05, 1.90)

2.72 (1.97, 3.45)

< 0.001

hsTnI (pg/ml)

50 (26, 107)

253.5 (75.5, 1539.5)

< 0.001

CK (U/L)

333 (125, 906)

1035 (435.5, 2597.3)

< 0.001

CK-MB (ng/ml)

3.63 (2.25, 7.14)

7.50 (4.39, 17.79)

< 0.001

α-HBDH (U/L)

351.0 (249.0, 537.8)

846.0 (552.4, 1439.3)

< 0.001

LDH (U/L)

538 (375, 846)

1422.5 (869.3, 2567.5)

< 0.001

  1. ALT: alanine aminotransferase; AST: aspartate aminotransferase; mAST: mitochondrial AST; cAST: cytosolic AST; ALP: alkaline phosphatase; GGT: gamma-glutamyltransferase; hsTnI: high-sensitivity troponin I; CK: creatine kinase; CK-MB: CK heart-type isoenzyme; α-HBDH: α-hydroxybutyrate dehydrogenase; LDH: lactate dehydrogenase